Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

Open accessibility options menu
  • 24/7
  • Buzz
  • Startups
  • VC
  • Finance@
  • Work@
  • Innovation
  • Opinions
  • Search
  • cleanSearch
  • Accesabillty
  • calcalist logo
bycalcalist logo
  • Homepage
  • Tags search
  • Fremanezumab

CTech 24/7

  • From PayPal roots to global exit: Inside Melio’s $3B sale to Xero
  • Digital farming company Fieldin appoints Iftach Birger as CEO
  • Digital farming company Fieldin appoints Iftach Birger as CEO
  • With AI in hiring, “it’s become harder to distinguish genuine depth,” says MineOS HR
More stories in CTech

Fremanezumab

1 stories about Fremanezumab
  • Teva. Photo: Sivan Farage

    Teva Discontinues Development of Cluster Headache Drug

    24.04.19|Tzally GreenbergUnder Teva’s brand name Ajovy, fremanezumab has already been approved in the U.S. and Europe as a preventative migraine treatment

Load more
Ctech Logo
Twitter
Twitter
Facebook
Facebook
NewsLetter
Newsletter
Contact Us
Contact Us
Rss
Rss
About CTech Terms of Use Privacy Policy
Developed by YIT UI & UX by Basch_Interactive